TRIPLE-1/FUJITSU
18.3.2019 16:02:06 CET | Business Wire | Press release
TRIPLE-1, Inc. (Representative Director: Takuya Yamaguchi) and Fujitsu Electronics Inc. (Representative Director: Junji Ogihara) have entered into a distributorship contract for a mining ASIC (application specific IC) “KAMIKAZE” that uses the world's most advanced 7nm process technology.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190318005034/en/
--- Background:
In the development market for mining ICs, which requires huge computing power and high power efficiency, the introduction of advanced process technology has been attempted positively and just like the development market for ICs for smartphones, which is one of the world's leading manufacture industries, the driving force for development came from the process miniaturization in the advanced semiconductor industry. As of 2019, there is a mover away from the mainstream 16nm process which had been the oligopoly of traditional Chinese region manufacturers to the state-of-the-art 7nm process. In the past, several companies, including Japanese companies, announced their entry into cutting-edge 7nm process development, but at the moment there are only a handful of manufacturers that have succeeded in commercializing ASIC (application specific IC).
--- Purpose / Perspective:
TRIPLE-1 is a semiconductor system development company established in
November 2016 and specializing in cutting-edge process technology.
Since
February 2017, we began to develop the ASIC (application specific IC)
"KAMIKAZE" for bitcoin mining adopting the world's most advanced 7nm
process technology.
About a year later in February 2018, we
announced the world's first tape-out (design completion) in the
state-of-the-art 7nm process for the same application and proceeded with
commercialization by TSMC (Taiwan), the world's largest foundry.
Currently
TRIPLE-1 is the only manufacturer of ASIC (application specific IC) that
adopts the state-of-the-art 7nm process technology in Japan and is the
only Japanese company that confronts the world in the cutting-edge
process development market.
Fujitsu Electronics develops a wide
range of products from various brands and manufacturers for markets
around the world by making full use of the global network spreading both
in Japan and abroad, centered on the "Fujitsu brand" that has continued
to be trusted for many years around the world.
Through the signing
of this distributorship contract, we will be able to spread the global
development potential of Fujitsu Electronics and the state-of-the-art
process development capabilities of TRIPLE-1 all over the world and
provide the real value of “Japanese manufacturing” to markets around the
world. On top of that, by establishing a long-term and strong
partnership, we will cooperate not only in mining ASIC (application
specific IC), but also in the development and deployment of leading-edge
products for various fields and applications.
--- TRIPLE-1 “KAMIKAZE” Product Features:
1. Adopts the world's most advanced 7nm process technology
Develops
the world's first "KAMIKAZE", an ASIC (application specific IC) for
bitcoin mining with using world's Leading-Edge company TSMC (Taiwan) ’s
7nm process technology and evaluates the first tape out (first
generation) version, Power Efficiency: 52 J / TH was realized (measured
on September 26, 2018).
2. Reduced energy consumption that contributes to energy resource
conservation
By operating at ultra-low voltage (0.3V or less)
and achieving low power consumption, it is possible to contribute to the
reduction of the enormous power required for mining and energy resource
conservation while maintaining a high performance.
3. High cooling efficiency from changes in packaging
In
order to achieve higher cooling efficiency, we adopted a structure
(exposed die - FCBGA) in which the backside of the silicon chip is
exposed on the package to achieve higher cooling efficiency, chip size
was encapsulated in 7 mm × 7 mm.
--- TRIPLE-1 outline:
Company Name: TRIPLE-1, Inc.
Corporate Headquarter:
7F IT
Bldg.Ⅱ,1-14-20 Hakataeki-Higashi, Hakata-ku Fukuoka-shi, Fukuoka, Japan
Representatives:
Representative Director CEO Takuya Yamaguchi
The capital: 3662
million 895 thousand and 398 yen (including the capital reserve)
--- Features of Fujitsu Electronics:
As an "Electronics General Trading Company" that contributes to the development of customers' businesses through offering an extensive lineup of Fujitsu brand products centered on LSIs with leading-edge technology and proprietary products, as well as domestic and overseas manufacturer products, with comprehensive support including sales, technology, solution services, logistic services and more. With 13 locations in Japan and 20 locations overseas, we have established a global distributor system that can propose a wide range of solutions, building a consistent network that can respond to customer requests in a timely manner, from product procurement to development and mass production.
--- Fujitsu Electronics outline:
Company Name: Fujitsu Electronics Inc.
Corporate Headquarter:
2-100-45,
Shin-Yokohama, Kohoku-Ku, Yokohama-shi, Kanagawa, Japan
Representatives:
President and Representative Director Junji Ogihara
The capital:
4,877,683,581 yen
Website: http://www.fujitsu.com/jp/fei/en/
--- About the trademark:
Proper nouns such as the product names listed are trademarks or registered trademarks of their respective owners.
View source version on businesswire.com: https://www.businesswire.com/news/home/20190318005034/en/
Contact:
Regarding this Press Release: TRIPLE-1, Inc. Public Relations Office GAKU MATSUSHIMA info@triple-1.com
Regarding Sales and Products: Fujitsu Electronics Inc. fei-triple1@dl.jp.fujitsu.com
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting28.3.2026 20:00:00 CET | Press release
Phase 3 data from the STOP-HS program demonstrate povorcitinib’s substantial and durable clinical efficacy through Week 54 in patients with moderate to severe hidradenitis suppurativa (HS). Through Week 54, clinically meaningful and durable responses were observed across all groups in both STOP-HS1 and STOP-HS2, with up to 71.4% of patients achieving HiSCR50. Improvements in clinical responses across high stringent thresholds were observed, with up to 57% of participants achieving HiSCR75 and up to 29% of participants achieving HiSCR100. Povorcitinib treatment led to consistent reductions across key inflammatory lesion types, with full resolution (ANdT=0) achieved in up to 20% of patients. Additionally, clinically meaningful improvements in quality-of-life measures, including skin pain and fatigue, were observed at Week 54. The overall safety profile of povorcitinib through 54 weeks is consistent with previously reported data, and both doses were well tolerated. Incyte (Nasdaq:INCY) to
Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care28.3.2026 20:00:00 CET | Press release
About 70% of patients treated with zasocitinib achieved clear or almost clear skin (sPGA 0/1) at week 16 in Phase 3 plaque psoriasis studies A significantly greater PASI 75 response rate versus placebo was observed as early as week 4 Safety profile consistent with Phase 2b studies with no new safety signals identified Takeda(TSE:4502/NYSE:TAK)today announced new data from the two pivotal Phase 3studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented as a late-breaking abstract at the 2026 American Academy of Dermatology (AAD) Annual Meeting, these data show that convenient once-daily oral zasocitinib demonstrated rapid and durable skin clearance with a safety profile consistent with Phase 2b studies.1,2 “Our goal in psoriasis treatment is clear or almost clear skin, and previously this has been achieved primarily with injectable therapies,” said Melinda Gooderham,
AAD 2026: Late-Breaking Nemolizumab Data Demonstrate Clinically Meaningful Benefits for Children Aged 2 to 11 With Moderate-to-Severe Atopic Dermatitis28.3.2026 16:00:00 CET | Press release
Pharmacokinetics, safety and efficacy clinical study data show that nemolizumab achieved clinically meaningful reductions in skin lesions and itch through Week 16, which were sustained up to a year in children aged 2 to 11 with moderate-to-severe atopic dermatitis1 These findings reinforce the previously established safety and efficacy of nemolizumab in adults and adolescents with moderate-to-severe atopic dermatitis, for which it is approved by multiple global regulatory authorities2,3 Up to 25% of children are affected by atopic dermatitis, and currently there are limited approved treatment options for children living with moderate-to-severe atopic dermatitis4,5 Galderma (SIX: GALD) today announced new phase II data showing that nemolizumab was well tolerated and effective in children (aged 2 to 11 years) with moderate-to-severe atopic dermatitis, with a clinically meaningful and sustained reduction in skin lesions and itch for up to a year.1 Results will be presented in a late-break
Angelalign Technology (6699.HK)Releases 2025 Results: Passion for Clinical Excellence Drives Worldwide Growth27.3.2026 20:56:00 CET | Press release
Angelalign Technology Inc. (6699.HK) (“Angel” or the “Company”) released its financial results for fiscal year 2025. During the reporting period, the Company continued to do well in both the global and China markets. Total case volume was 532,400, which increased 48.1%, revenue was USD 370.3 million, which increased 37.8%, and adjusted net profit was USD 43.8 million, which increased 63.0%. The results were driven by Angel’s passion for clinical excellence and its open and inclusive culture that empowers talented people to work together to meet customer needs, the Company said. Fox Hu, CEO of Angel, stated: “The clear aligner industry is complex and multidisciplinary. It requires top-tier technical and operational talent along with seamless collaboration among professionals from diverse geographies. Angel’s open and inclusive culture attracts professionals who share a passion for clinical excellence and a dedication to bringing outstanding products and services to customers. This melti
Axway Positioned as a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment27.3.2026 18:46:00 CET | Press release
Axway, a 74Software company (Euronext: 74SW) and global leader in federated API management and enterprise integration, has been named a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment.1 Axway Amplify securely connects, orchestrates, and automates data integration. Organizations in financial services, manufacturing, healthcare, and other industries rely on Amplify to modernize integrations and confidently unlock data to deliver superior digital services faster. The report notes: “The platform benefits from Axway’s long-standing experience in B2B integration, secure file transfer, and legacy connectivity, providing differentiated capabilities for organizations that need to expose and control APIs around core systems that are not cloud-native.”1 This multi-pattern expertise in security, integration, and federated governance — built during the early phases of the API-driven digital transformation — becomes especially critical as enterprises seek to govern dat
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
